Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients

Abstract

Incremental cost-effectiveness analysis indicated the dominance of voriconazole because of both lower costs and greater efficacy.

Invasive Pulmonary Aspergillosis Complicated with Pneumopericardium and Pneumothorax in an Adult Patient with Acute Lymphoblastic Leukaemia, Successfully Treated with Amphotericin B: Case Report and a Review

“…It was shown to have a better pericardial penetration compared to other drugs [17]. Further, it was also shown to be more cost effective compared to amphotericin B with a 10% lower overall treatment cost per patient [18]. Although severe hepatotoxicity is rare, this is unpredictable since there is inter-individual and intra-individual variability in voriconazole, plasma levels [7].…”

Acute Lymphocytic Leukemia with Superimposed Invasive Aspergillosis and Pneumopericardium Successfully Treated with Voriconazole

“…All other previous cases of Aspergillus-associated pneumopericardium were treated with conventional amphotericin B therapy with mixed outcomes and prolonged hospital courses (2)(3)(4)(5). Based on the limited available data, however, voriconazole appears to have superior pericardial penetration compared with other agents, and current treatment guidelines favor this agent in the treatment of invasive aspergillosis (12)(13)(14)(15). Medical management with voriconazole in our case resulted in early symptomatic recovery in a high-risk cachectic patient.…”

Combination antifungal therapy: what can and should we expect?

“…In a recent pharmacoeconomic analysis based on this randomized trial, the average costs of managing a patient receiving voriconazole were $30 664. 43 Costs for survivors were even higher (approximately $43 000). Although more than half of these costs were attributed to costs of hospitalization, drug therapy costs were substantial and would be increased further in a study of combination antifungal therapy.…”